期刊文献+

COPD患者诱导痰的细胞学分析及其临床意义 被引量:6

下载PDF
导出
摘要 目的:探讨不同时期慢性阻塞性肺疾病(COPD)患者及健康对照者诱导痰中细胞组成的变化,COPD患者诱导痰中细胞总数及中性粒细胞百分比与气流受限的关系。方法:对33例急性加重期COPD患者(A组)、27例稳定期COPD患者(B组)、14例健康吸烟者(C组)、14例健康不吸烟者(D组)进行肺功能测定及痰诱导,痰液处理后沉渣作细胞学分析。结果:(1)A、B、C、D组诱导痰中细胞总数分别为(10.2±5.28)×106/mL、(4.4±1.63)×106/mL、(3.0±1.45)×106/mL、(1.9±1.07)×106/mL,细胞分类中A、B、C组以中性粒细胞为主,分别为(70.9±13.6)%、(57.0±10.9)%、(52.3±11.1)%,而在D组中则以中性粒细胞、淋巴细胞和巨噬细胞为主,分别为(34.8±6.9)%、(25.6±8.2)%、(26.9±7.3)%;(2)诱导痰中细胞总数及中性粒细胞百分比与肺功能指标呈负相关关系。结论:(1)COPD急性加重期患者、稳定期患者、健康吸烟者诱导痰细胞以中性粒细胞为主,不吸烟健康者诱导痰细胞以中性粒细胞、淋巴细胞和巨噬细胞为主;(2)气道局部中性粒细胞增多与COPD患者气流受限存在密切的关系。
出处 《实用医学杂志》 CAS 2007年第3期304-306,共3页 The Journal of Practical Medicine
基金 广东省自然科学基金项目(编号:04009385) 广东省卫生厅基金项目(编号:A2004188)
  • 相关文献

参考文献7

  • 1曾勉,吴健锋,谢灿茂,严英硕,陈冬梅,禤建美.慢性阻塞性肺疾病急性加重期患者规范化痰诱导安全性的初步研究[J].中华结核和呼吸杂志,2005,28(4):238-241. 被引量:45
  • 2Kips J C,Inman M D,Jayaram L,et al.The use of induced sputum in clinical trials[J].Eur Respir J,2002,20(Suppl):47s-50s.
  • 3Krisiukeniene A,Sitkauskiene B,Malakauskas K,et al.Peculiarities of induced sputum inflammatory cell counts in allergic versus non-allergic asthma[J].Medicina(Kaunas),2005,41 (3):196-202.
  • 4Domagala K J,Maskey W M,Kraszewska I.The cellular composition and macrophage phenotype in induced sputum in smokers and ex-smokers with COPD[J].Chest,2003,123(4):1054-1059.
  • 5戴路明,杨玉萍,方利洲,刘凌,李兴文,郑圆圆.慢性支气管炎、慢性阻塞性肺气肿患者诱导痰中细胞分析[J].昆明医学院学报,2000,21(4):38-41. 被引量:3
  • 6Balzano G,Stefanelli F,Iorio C,et al.Eosinophilie inflammation in stable chronic obstructive pulmonary disease.Relationship with neutrophils and airway function[J].Am J Respir Crit Care Med,1999,160(5):1486-1492.
  • 7Donnell R A,Peebles C,Ward J A,et al.Relationship between peripheral airway dysfunction,airway obstruction,and neutrophilic inflammation in COPD[J].Thorax,2004,59(7):837-842.

二级参考文献13

  • 1Pin I,Gibson PG,Kolendowicz R,et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax,1992,47:25-29.
  • 2Sutherland ER,Pak J,Langmack EL,et al. Safety of sputum induction in moderate-to-severe chronic obstructive pulmonary disease. Respir Med,2002,96:482-486.
  • 3Fabbri LM,Hurd SS,GOLD Scientific Committee. Global strategy for the diagnosis,management and prevention of COPD:2003 update. Eur Respir J,2003,22:1-2.
  • 4Celli BR,MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J,2004,23:932-946.
  • 5Bach PB,Brown C,Gelfand SE,et al. Management of acute exacerbations of chronic obstructive pulmonary disease:a summary and appraisal of published evidence. Ann Intern Med,2001,134:600-620.
  • 6Vignola AM,Rennar SI,Hargreave FE,et al. Standardised methodology of sputum induction and processing. Future directions. Eur Respir J Suppl,2002,37:51s-55s.
  • 7Tsoumakidou M,Tzanakis N,Siafakas NM. Induced sputum in the investigation of airway inflammation of COPD. Respir Med,2003,97:863-871.
  • 8Vlachos-Mayer H,Leigh R,Sharon RF,et al. Success and safety of sputum induction in the clinical setting. Eur Respir J,2000,16:997-1000.
  • 9Rohde G,Wiethege A,Borg I,et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation:a case-control study. Thorax,2003,58:37-42.
  • 10Leigh R,Sharon RF,Efthimiadis A,et al. Diagnosis of left-ventricular dysfunction from induced sputum examination. Lancet,1999,354:833-834.

共引文献46

同被引文献42

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部